<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003130</url>
  </required_header>
  <id_info>
    <org_study_id>43CH1508</org_study_id>
    <nct_id>NCT03003130</nct_id>
  </id_info>
  <brief_title>Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds</brief_title>
  <official_title>A Randomized, Multi-center, Evaluator-blinded Study to Evaluate the Efficacy and Safety of Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, split face, multicenter study to evaluate the efficacy and safety of
      Restylane Defyne compared to Restylane in correction of NLFs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">September 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Wrinkle Severity Rating Scale (WSRS) at 6 month</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Nasolabial Folds in Chinese Population</condition>
  <arm_group>
    <arm_group_label>Restylane Defyne</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection and optional touch up injection with Restylane Defyne in NLF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single injection and optional touch up injection with Restylane in NLF</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Defyne</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>Restylane Defyne</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>Restylane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent.

          2. Men or women aged 18 years of age or older of Chinese origin.

          3. Subjects willing to abstain from any other facial plastic surgical or cosmetic
             procedures below the level of the lower orbital rim for the duration of the study.

          4. Intent to undergo correction of both NLFs with a wrinkle severity in WSRS of either 3
             on both sides or 4 on both sides, as assessed by the blinded evaluator.

        Exclusion Criteria:

          1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) Gel
             and/or local anesthetics, e.g., lidocaine or other amide-type anesthetics.

          2. Previous tissue revitalization treatment below the level of the lower orbital rim
             within 6 months before treatment.

          3. Previous surgery or tattoo in the area to be treated.

          4. Previous tissue augmentation therapy or contouring with any permanent
             (nonbiodegradable) or semi-permanent facial tissue augmentation therapy or autologous
             fat or permanent implant below the level of the lower orbital rim.

          5. Previous use of neurotoxins or any hyaluronic acid based or collagen based
             biodegradable facial tissue augmentation therapy below the level of the lower orbital
             rim within 12 months before treatment.

          6. Scars or deformities, active skin disease, inflammation or related conditions such as
             infection, perioral dermatitis, seborrheic dermatitis, eczema, rosacea, acne,
             psoriasis, and herpes zoster near or in the area to be treated.

          7. Other condition preventing the subject from entering the study in the Investigator's
             opinion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>QmedAB</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Q-Med AB</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Q-Med AB</last_name>
      <phone>021-23159666</phone>
      <email>Q-Med@galderma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2016</study_first_submitted>
  <study_first_submitted_qc>December 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2016</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyaluronic acid</keyword>
  <keyword>Comparative study</keyword>
  <keyword>NLF</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

